Leaders in Pharmaceutical Business Intelligence (LPBI) Group

11th Annual Recombinant Protein Therapeutics: Fusion Proteins and Beyond, January 19-20, 2015, San Diego, CA

Reporter: Aviva Lev-Ari, PhD, RN

Conference AGENDA

http://www.chi-peptalk.com/recombinant-protein-therapeutics

Cambridge Healthtech Institute’s PepTalk presents its 11th Annual Recombinant Protein Therapeutics: Fusion Proteins and Beyond, January 19-20, 2015, San Diego, CA

Dr. Ralf Schumacher, Site Head, Large Molecule Research Penzberg, and pRED Center Manager at Roche Diagnostics GmbH will share Roche’s strategies to discover, design, develop, and deliver new innovative therapeutic biologics during the Opening Keynote Address at the upcoming meeting in San Diego.

KEYNOTE ADDRESS – January 19, 9:10 am

Biologics have become a key component in the treatment of various life-threatening diseases. The majority of these drugs are classical monoclonal antibodies. In order to discover and develop differentiated monoclonal antibodies, Roche’s strategy is based on engineering technologies. ADCC-enhancement, multi-pathway-inhibition, specific tumor-targeting of pharmacophores and blood-brain-barrier crossing are examples for successfully engineered mAbs and fusion proteins. In this presentation, I will describe Roche’s strategies to design such molecules, give examples but will also address challenges for technical development.

Learn More  |   Download Brochure

WHEN: January 19-20, 2015

WHERE: Town and Country Resort & Convention Center, San Diego, California

(Part of CHI’s 14th Annual PepTalk: The Protein Science Week)

DOWNLOAD PDF: http://bit.ly/2015pdf

TO REGISTER:

Call toll free: +1-888-999-6288

Online: http://bit.ly/PTK2015Reg

Contact: David Cunningham for Group Discounts at 781-972-5472

ABOUT: Ralf Schumacher is Head of Large Molecule Research (LMR) Penzberg (Germany) of the Roche Pharma Division. This Center of Excellence for all Discovery and Early Technical Development Activities for Therapeutic Proteins within Roche Pharma Research and Early Development (pRED) provides innovative drug candidates for various indications. LMR has invented several breakthrough technologies in the context of antibody engineering. LMR’s mission is to provide tailor made solutions for the given biological scene. Technical development is closely integrated in all design activities.

Ralf holds a Diploma in Biology from the Rheinisch Westfälische Technische Hochschule, Aachen, and a Ph.D. in Molecular Biology from the Max-Planck-Institute for Biochemistry, Martinsried.

Ralf joined Boehringer Mannheim, Research Oncology, as a Senior Scientist in the Department for Screening Technologies in 1996. After the take over by Roche in 1997 he had several positions, i.e. Preclinical Project Leader of several Oncology Projects, Biopharmaceuticals Program Manager, Technical Project Leader for Biologics Projects, Head of Biopharmaceuticals Program Management, Head of Protein Discovery TPI and  Head of Biologics Technical Sciences TPI. Since 2000 he was one of the pioneers building up the internal efforts to discover and develop Therapeutic Proteins for different indications within Pharma Research. Until today more than 18 molecules were brought into clinical development (the most advanced project is in Phase 3 of clinical development). Ralf was the inventor and pre-clinical project leader for Teptrotumumab, an antibody in clinical phase 2 development.

Agenda-At-A-Glance

Next-Generation Biologics

KEYNOTE PRESENTATION Roche’s Strategies to Discover, Design, Develop, and Deliver New Innovative Therapeutic Biologics

Ralf Schumacher, Ph.D., Site Head, Large Molecule Research Penzberg, and pRED Center Manager, Roche Diagnostics GmbH

FEATURED PRESENTATION Monomeric Fc Fusion Clotting Factors for the Treatment of Hemophilia

Jennifer Dumont, Ph.D., Director, Medical Affairs, Biogen Idec, Inc.

Engineering Breakthroughs

A Small Biologic Alternative to PCSK9 Antibodies: Pharmacologic Profile and Demonstration of Robust LDL Lowering with an Anti-PCSK9 Adnectin

Tracy Mitchell, Ph.D., Principal Scientist, Bristol Myers-Squibb Co.

Development of an Intein-Based Conjugation Platform for the Synthesis of Fc-Fusion Proteins

Oliver Thiel, Ph.D., Principal Scientist, Chemical Process Research & Development, Amgen, Inc.

A Bi-Functional Antibody-Receptor Domain Fusion Protein Simultaneously Targeting IGF-IR and VEGF for Degradation

Yang Shen, Ph.D., Director, Antibody Technology, and Research Advisor, Antibody Engineering, ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

Enhancing Properties

Unravelling the Molecular Basis of Host Cell-Specific Glycosylation and Species-Specific Pharmacokinetics

Catherine Huntington, Ph.D., Research Scientist II, Antibody Discovery and Protein Engineering (ADPE), MedImmune, LLC

Enhancing Stability of the Therapeutic Enzyme L-Asparaginase by Biocompatible Nanoparticles

Manfred Konrad, Ph.D., Research Director, Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry

Manufacturing of Half-Life Extended Fusion Proteins: Current Trends and Challenges

Stefan Schmidt, Ph.D., Vice President, DSP, Rentschler Biotechnology

Conquering Disease

A Neuroprotective Brain-Penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis

Eliezer Masliah, M.D., Professor, Neuroscience and Pathology, University of California at San Diego

Novel Human Resistant Mutant that Acts as Antagonist Reduced Body Weight Gain and Restored Insulin Responsiveness in Mice Fed High Fat Diet

Arieh Gertler, Ph.D., CEO, Protein Laboratories Rehovot; Professor-Emeritus and Head of Research Team, Biochemistry, The Hebrew University of Jerusalem

Local Inhibition of Cytokine Signaling to Treat Anterior and Posterior Ocular Disorders

Eric Furfine, Ph.D., CSO, Eleven Biotherapeutics

Conquering Cancer

Late Stage Development of a Chimeric Antibody

Manfred Schuster, Ph.D., COO, Apeiron Biologics AG

A Recombinant Immunotoxin for Cancer Treatment with Low Immunogenicity by Identification and Silencing of Human T Cell Epitopes

Ronit Mazor, Ph.D., Research Fellow, Lab for Molecular Biology (LMB), NCI/NIH

Engineering Flexibility

Engineered Affibody Molecules in Multiple Formats for Targeted Therapy

Fredrik Frejd, Ph.D., Vice President and CSO, Affibody AB

DeBouganin Fusion Proteins: A “Fit for Purpose” ADC Drug Design

Glen C. MacDonald, Ph.D., CSO, Viventia Bio, Inc.

————————————————————————

You may also be interested in the following Short Courses*

(SC1) Production Challenges for Complex Biologics: ADCs, Bispecifics and Fusion Proteins

(SC7) Targeting of GPCRs with Monoclonal Antibodies >>>Detailed Agenda

(SC8) Affecting Effector Function: Engineering the Fc Region

For event details, visit

CHI-PepTalk.com/recombinant-protein-therapeutics

Premier Sponsor

For sponsorship & exhibit  information, contact:

(Companies A-K)

Jason Gerardi

781-972-5452

jgerardi@healthtech.com

(Companies L-Z)

Carol Dinerstein

781-972-5471

dinerstein@healthtech.com

SOURCE

11th Annual Recombinant Protein Therapeutics Conference <nicolel@healthtech.com>